FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109134480> ?p ?o ?g. }

• W2109134480 abstract "On September 12, 1957 E. Donnall Thomas and collegues reported in the New England Journal of Medicine [1] on their paradigm shift in the treatment of leukemia by applying intravenous infusion of bone marrow after irradiation and chemotherapy. This was the hour of birth of allogeneic stem cell transplantation which is based on the idea to replace malignant transformed bone marrow by healthy bone marrow of another individual. Graft rejection, graft-versus-host disease, leukemic progression, and life-threatening opportunistic infections were the major reasons that none the patients survived longer than 100 days, and great pessimism predominated in the scientific world.As recapitulated by Frederick R. Appelbaum [2] on the occasion of the 50th anniversary of allogeneic stem cell transplantation Thomas was convinced that donor selection was the key to overcome the assumed incompatibility. The discovery of the dog and human leukocyte antigen system (DLA, HLA) were milestones to learn more about the impact of genetic polymorphisms, to investigate the cause of graft-versus-host disease, and to deal carefully with the donor T-cell-related alloreactivity in respect to initial eradication of residual tumor cells and immunosurveillance thereafter. ‘After all the disappointments of clinical marrow transplants in the late 1950s and early 1960s, there was general pessimism about the field and many of the early investigators moved on to other studies. Nevertheless, improvement in transfusion medicine, the treatment of infections and especially an improved understanding of the importance of HLA typing encouraged a renewed attack on the clinical application of marrow grafts', summarized Thomas his pioneering work [3].Nowadays, about 50,000 autologous and allogeneic stem cell transplantations (related/unrelated) per year are performed worldwide in more than 500 transplantation centers [2]. This success story is strongly linked to the special topic of this issue of Transfusion Medicine and Hemotherapy, that is to say the discovery and use of hematopoietic growth factors in transfusion medicine and cellular therapy and their pharmaceutical manufacturing. For example, mouse G-CSF was first purified by Metcalf's group at the Walter and Eliza Hall Institute in Australia in 1983 [4], whereas the human molecule was cloned by two independent groups in Japan [5] and USA [6] in 1986. Notably, granulocyte colony-stimulating factor (G-CSF) stimulates the amplification of hematopoietic stem cells and myeloid progenitor cells in the bone marrow compartment and facilitates their transendothelial migration into the bloodstream. This phenomenon is not only advantageous for patients with severe chemotherapy-related neutropenia in order to maintain their immune competence against foreign pathogens, but also of paramount importance for collecting sufficient doses of hematopoietic stem cells or neutrophils from the peripheral blood.Therefore, the introduction of G-CSF for stem cell mobilization revolutionized the practicability of both autologous and allogeneic transplantations. Meanwhile, more than two decades of experiences are on hand to legitimate the use in healthy volunteers after informed consent. The non-inferiority of peripheral blood stem cells in comparison with bone marrow from unrelated donors was recently demonstrated by Anasetti et al. [7] for the Blood and Marrow Transplant Clinical Trials Network. In the current issue, two contributions from the Department of Internal Medicine I at the Technical University of Dresden deal with the risk-benefit assessment of G-CSF in healthy individuals donating either stem cells or granulocytes [8, 9].It is well known that in a minority, of patients, and – with some other implications – also in very few volunteer donors, stem cells are not mobilized into the circulation sufficiently. In an autologous setting, these ‘poor’ mobilizers are at risk not to be transplanted unless multiple procedures allow for the collection of at least a single transplant dose or another alternative becomes attractive such as the use of an additional drug with a different mode of action then G-CSF. Plerixafor is such a drug that helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream by antagonizing the CX chemokine receptor 4 (CXCR4) and its interaction with stromal derived factor 1 (SDF1). Plerixafor is approved by US Food and Drug Administration (FDA) to be used in combination with G-CSF for patients with multiple myeloma and non-Hodgkin's lymphoma. The physiology and pharmacology of plerixafor is illustrated in a comprehensive review written by S. Fricker, Sanofi-Genzyme [10], whereas the current clinical indications after the European marketing authorization took place in 2009 are summarized by S. Fruehauf [11]. Humpe et al. [11] have added a paper with original data of 14 poor mobilizers who underwent large-volume apheresis after plerixafor supplementation.The incredible progress in hematopoietic stem cell transplantation has been made possible by recent advances and new avenues in fields such as basic research in stem cell biology (long-term engraftment), growth factor-driven lineage cell fate, collection of mobilized stem cells via leukapheresis, sophisticated graft manipulation techniques (T-cell depletion), high-resolution HLA typing, and the charitable recruitment of millions of unrelated volunteer donors. The dream will become true that every patient will have at least one suitable donor, including those with a non-perfect tissue match who allow for alternative transplantation options by using cord blood (double or ex vivo expanded) or haploidentical donors such as the patient's parents." @default.
• W2109134480 created "2016-06-24" @default.
• W2109134480 creator A5009374289 @default.
• W2109134480 creator A5033434119 @default.
• W2109134480 date "2013-01-01" @default.
• W2109134480 modified "2023-09-24" @default.
• W2109134480 title "Hematopoietic Growth Factors in Transfusion Medicine and Cellular Therapy - Part II" @default.
• W2109134480 cites W1986436077 @default.
• W2109134480 cites W2001611987 @default.
• W2109134480 cites W2007950619 @default.
• W2109134480 cites W2012016826 @default.
• W2109134480 cites W2022999545 @default.
• W2109134480 cites W2024902315 @default.
• W2109134480 cites W2027753510 @default.
• W2109134480 cites W2030428868 @default.
• W2109134480 cites W2032573070 @default.
• W2109134480 cites W2036631709 @default.
• W2109134480 cites W2046428819 @default.
• W2109134480 cites W2046994513 @default.
• W2109134480 cites W2058788010 @default.
• W2109134480 cites W2075580305 @default.
• W2109134480 cites W2090229245 @default.
• W2109134480 cites W2092368843 @default.
• W2109134480 cites W2094488645 @default.
• W2109134480 cites W2126021331 @default.
• W2109134480 cites W627822254 @default.
• W2109134480 doi "https://doi.org/10.1159/000354964" @default.
• W2109134480 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3822279" @default.
• W2109134480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24273482" @default.
• W2109134480 hasPublicationYear "2013" @default.
• W2109134480 type Work @default.
• W2109134480 sameAs 2109134480 @default.
• W2109134480 citedByCount "0" @default.
• W2109134480 crossrefType "journal-article" @default.
• W2109134480 hasAuthorship W2109134480A5009374289 @default.
• W2109134480 hasAuthorship W2109134480A5033434119 @default.
• W2109134480 hasBestOaLocation W21091344801 @default.
• W2109134480 hasConcept C109159458 @default.
• W2109134480 hasConcept C126322002 @default.
• W2109134480 hasConcept C147483822 @default.
• W2109134480 hasConcept C188280979 @default.
• W2109134480 hasConcept C203014093 @default.
• W2109134480 hasConcept C2776885095 @default.
• W2109134480 hasConcept C2777408962 @default.
• W2109134480 hasConcept C2778461978 @default.
• W2109134480 hasConcept C2779015954 @default.
• W2109134480 hasConcept C2779134260 @default.
• W2109134480 hasConcept C2780007613 @default.
• W2109134480 hasConcept C2780014101 @default.
• W2109134480 hasConcept C28328180 @default.
• W2109134480 hasConcept C2911091166 @default.
• W2109134480 hasConcept C54355233 @default.
• W2109134480 hasConcept C71924100 @default.
• W2109134480 hasConcept C79592252 @default.
• W2109134480 hasConcept C86803240 @default.
• W2109134480 hasConcept C8891405 @default.
• W2109134480 hasConceptScore W2109134480C109159458 @default.
• W2109134480 hasConceptScore W2109134480C126322002 @default.
• W2109134480 hasConceptScore W2109134480C147483822 @default.
• W2109134480 hasConceptScore W2109134480C188280979 @default.
• W2109134480 hasConceptScore W2109134480C203014093 @default.
• W2109134480 hasConceptScore W2109134480C2776885095 @default.
• W2109134480 hasConceptScore W2109134480C2777408962 @default.
• W2109134480 hasConceptScore W2109134480C2778461978 @default.
• W2109134480 hasConceptScore W2109134480C2779015954 @default.
• W2109134480 hasConceptScore W2109134480C2779134260 @default.
• W2109134480 hasConceptScore W2109134480C2780007613 @default.
• W2109134480 hasConceptScore W2109134480C2780014101 @default.
• W2109134480 hasConceptScore W2109134480C28328180 @default.
• W2109134480 hasConceptScore W2109134480C2911091166 @default.
• W2109134480 hasConceptScore W2109134480C54355233 @default.
• W2109134480 hasConceptScore W2109134480C71924100 @default.
• W2109134480 hasConceptScore W2109134480C79592252 @default.
• W2109134480 hasConceptScore W2109134480C86803240 @default.
• W2109134480 hasConceptScore W2109134480C8891405 @default.
• W2109134480 hasLocation W21091344801 @default.
• W2109134480 hasLocation W21091344802 @default.
• W2109134480 hasLocation W21091344803 @default.
• W2109134480 hasLocation W21091344804 @default.
• W2109134480 hasOpenAccess W2109134480 @default.
• W2109134480 hasPrimaryLocation W21091344801 @default.
• W2109134480 hasRelatedWork W1968774615 @default.
• W2109134480 hasRelatedWork W2021386299 @default.
• W2109134480 hasRelatedWork W2023525239 @default.
• W2109134480 hasRelatedWork W2026490282 @default.
• W2109134480 hasRelatedWork W2051446802 @default.
• W2109134480 hasRelatedWork W2068120077 @default.
• W2109134480 hasRelatedWork W2068919238 @default.
• W2109134480 hasRelatedWork W2070094082 @default.
• W2109134480 hasRelatedWork W2073611419 @default.
• W2109134480 hasRelatedWork W2076057150 @default.
• W2109134480 hasRelatedWork W2086060643 @default.
• W2109134480 hasRelatedWork W2105004709 @default.
• W2109134480 hasRelatedWork W2146162698 @default.
• W2109134480 hasRelatedWork W2171644873 @default.
• W2109134480 hasRelatedWork W2181527372 @default.
• W2109134480 hasRelatedWork W2185033940 @default.
• W2109134480 hasRelatedWork W2284574660 @default.
• W2109134480 hasRelatedWork W2412925129 @default.
• W2109134480 hasRelatedWork W2496827925 @default.

• next